See related NovoNorm tab information 
 
Manufacturer Novo Nordisk 
Distributor DKSH 
Contents Repaglinide
Indications Type II diabetes.
Dosage Initially 0.5 mg, titrated on wkly or bi-wkly basis. If patients are transferred from another oral hypoglycemic agent, starting dose: 1 mg. Max: 4 mg single dose or 16 mg daily dose.
Administration Should be taken with food (Usually taken w/in 15 min of the meal but time may vary from immediately before to 30 min before the meal.).
Contraindications Type 1 diabetes. Diabetic ketoacidosis w/ or w/o coma. Pregnancy, lactation. Childn <12 yr. Severe renal or hepatic function disorders. Concomitant therapy w/ medicinal products which are CYP3A4, CYP2C8 inhibitors or inducers.
Special Precautions Patients >75 yr.
Adverse Drug Reactions Hypoglycemia, transient visual disturbances, GI disturbances. Hypersensitivity reactions of the skin.
View ADR Monitoring Form
Drug Interactions MAOIs, nonselective β-blockers, ACE inhibitors, NSAIDs, salicylates, octreotide, alcohol & anabolic steroids. OC, thiazides, corticosteroids, danazol, thyroid hormones & sympathomimetics, sulphonylurea.
View more drug interactions with NovoNorm
Pregnancy Category (US FDA)      
     
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. 

Presentation/Packing
Form Packing Photo
NovoNorm tablet  NovoNorm 0.5 mg x 90's
NovoNorm 1 mg x 90's
NovoNorm 2 mg x 90's
 

 
Manufacturer: Novo Nordisk
 
Distributor: DKSH